TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05466695
Drug: Tadalafil 5mg/sildenafil 25 mg
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will use daily tadalafil or daily sildenafil for 2 months blood sample will be obtained before and after 2 months and also IIEF-5 score for clinical response
Study: NCT05221775
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: XELOX regimen combined with GLS-010 and different doses of Lenvatinib
Study: NCT05300841
Drug: dydrogesterone 20 mg /d (Duphaston, Abott Healthcare , Egypt)
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pretreatment with dydrogestrone (Duphaston, Abott Healthcare, Egypt) will be administered during the cycle preceding the ICSI cycle in a daily dose of 20 mg/ day starting 10 days before the presumed onset of menses
Study: NCT04941937
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg/d QW
Study: NCT04941937
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mg/d, Po. on day1-28
Study: NCT04941937
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PO,Lenalidomide 25mg once daily from D1-21
Study: NCT04941937
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle, PO.
Study: NCT04941937
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
Study: NCT05911438
Drug: Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO)
Normalized name: ferric derisomaltose Injection
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferric Derisomaltose Injection (Monoferric): 1000 mg, intravenous infusion 6±2 days before surgery; Human Erythropoietin Injection (EPIAO): 36000 IU, subcutaneous injection 6±2 days before surgery and 3±1 days after surgery.
Study: NCT06329882
Drug: Sitagliptin 100mg
Normalized name: Sitagliptin 100mg Oral tablet
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes
Study: NCT06329882
Drug: Doxycyclin
Normalized name: Doxycyclin
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth.
Study: NCT04095689
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microtubule-targeting drug (inhibits microtubule depolymerization)
Study: NCT04095689
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Programmed cell death-1 (PD-1) inhibitor
Study: NCT00050973
Drug: bexarotene
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT06246071
Drug: TYK-00540
Normalized name: Tykerb
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TYK-00540 PO, BID
Study: NCT06008483
Drug: 153-Sm-DOTMP (Samarium-153-DOTMP)
Normalized name: SM-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an open-label, unblinded, multi-center, dose-finding study of 153Sm-DOTMP (CycloSam®) to identify the MTD of 153Sm- DOTMP, given as a tandemly administered pair of doses to subjects with solid tumors visible on bone scan.
Study: NCT01309022
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
Study: NCT01309022
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
Study: NCT01309022
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
Study: NCT04749394
Drug: Camrelizumab, PD-1 monoclonal antibody
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab 200mg IV, Q3W, until clinical progression/deterioration or confirmed radiological progression, or up to 1 year.
Study: NCT05077098
Drug: ADXS-504
Normalized name: ADX 102
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADXS-504 will be administered as monotherapy at 2 dose levels. Subjects who are assigned to receive Dose Level 1 (DL1) will be administered ADXS-504 at a dose of 1×107 CFU q4 weeks (±3 days) from Week 1 to Week 21. Subjects who are assigned to receive Dose Level 2 (DL2) will be administered ADXS-504 at a dose of 1×108 CFU q4 weeks (±3 days; Week 1 to Week 21). All 3-6 subjects must be enrolled in DL1, and DL1 must be confirmed safe, before enrollment for DL2 may begin. For both dose levels, these doses are followed by maintenance dosing at each respective dose level given every 12 (q12) weeks (±3 days) for 4 doses for overall total of 10 doses of the study treatment. If DL1 is deemed to exceed the MTD, dose reduction of ADXS-504 to DL-1 (1×106 CFU) may proceed. Dose level -1, intermediate dose levels or expansion of a cohort may also be further evaluated if recommended by the Investigator and Advaxis in future amendments.
Study: NCT05281770
Drug: Erenumab
Normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: treatment with erenumab as chosen by treating physician
Study: NCT05281770
Drug: Fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: treatment with fremanezumab as chosen by treating physician
Study: NCT05281770
Drug: Galcanezumab
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: treatment with galcanezumab as chosen by treating physician
Study: NCT05004974
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab is administered every 3 weeks (200mg, IV).
Study: NCT05004974
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pemigatinib 13.5 mg once daily (QD) orally, continuous administration.
Study: NCT06508372
Drug: Topical thymoquinone Ointment
Normalized name: hydroquinone Topical Solution
DrugBank: Thymoquinone (DB16447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One plaque per patient on one side of the body will be selected, whose diameter would not exceed 5-10 cm2 to apply Thymoquinone ointment as a monotherapeutic ttt twice daily for 3 months.
Study: NCT04988282
Drug: Methylprednisolone Tablet
Normalized name: Methylprednisolone Tablets
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks
Study: NCT04816604
Drug: GB002 (seralutinib)
Normalized name: Seralutinib
DrugBank: Seralutinib (DB18072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing GB002 (seralutinib)
Study: NCT04833959
Drug: 89Zr-panitumumab
Normalized name: 89Zr-panitumumab
DrugBank: Zirconium panitumumab Zr-89 (DB19228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaging Agent
Study: NCT04676867
Drug: Dalcetrapib
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 300 mg Film-Coated Tablets
Study: NCT06105658
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)
Study: NCT06105658
Drug: Decetabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
Study: NCT06105658
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
Study: NCT00788580
Drug: pazopanib hydrochloride
Normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00788580
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00002070
Drug: Sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002070
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05489900
Drug: Dexmedetomidine Hydrochloride
Normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine is a specific and potent α2-adrenergic agonist. By acting directly on the sympathetic nervous system, they can exert beneficial effects on the immune system through neuroimmune interactions. Its administration can induce an anti-inflammatory response due to different central (increase parasympathetic tone, promoting control of the inflammatory condition) and peripheral effects (stimulating innate immunity).(MILLER, 2015).~Venous blood samples were collected at three times (T1, T2 and T3): Before anesthetic induction with collection in the preoperative environment on the day of surgery or during venoclysis before anesthetic induction (sample 1, T1); 6 hours after starting orifice closure and completion of drug or placebo infusion (sample 2, T2); and the last blood sample will be collected by me on the morning after the postoperative period, close to hospital discharge - 24h (sample 3, T3).
Study: NCT06055816
Drug: Endostar and Envafolimab
Normalized name: cytarabine and daunorubicin
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.
Study: NCT06158230
Drug: Pizotifen
Normalized name: Pizotifen
DrugBank: Pizotifen (DB06153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizotifen will be given only at night time to avoid daytime somnolence. Starting dose will be 0.5mg then gradually increased to 1.5 mg
Study: NCT06158230
Drug: Amitriptyline-propranolol
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline will be given at bedtime only, starting at 10 mg daily and gradually increasing to 25 mg daily.~Propranolol will be started in 40 mg daily in divided doses, which gradually increases to 80 mg daily in divided doses
Study: NCT05202821
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First group will be receiving Fluoride varnish every 3 months
Study: NCT06347250
Drug: Lidocaine Hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).
Study: NCT04668235
Drug: AZVUDINE
Normalized name: Azvudine
DrugBank: Azvudine (DB16407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 tablets QD + standard treatment for up to 14 days
Study: NCT04668235
Drug: AZVUDINE placebo
DrugBank: Azvudine (DB16407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 tablets QD + standard treatment for up to 14 days
Study: NCT05045170
Drug: Influence of propofol sedation on memory consolidation and 'working memory'
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to propofol sedation (stage 1), 5-10 minutes after the start of propofol sedation (stage 2), 10 minutes after propofol sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
Study: NCT05045170
Drug: Influence of dexmedetomidine sedation on memory consolidation and 'working memory'
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to dexmedetomidine sedation (stage 1), 5-10 minutes after the start of dexmedetomidine sedation (stage 2), 10 minutes after dexmedetomidine sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
Study: NCT04576078
Drug: Oral nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h. Oral nefopam is prepared ex-tempore from the intravenous formulation adding a taste masking compound by a non-caring nurse following detailed instructions.
Study: NCT04988997
Drug: Vurolenatide 50mg/PBO
DrugBank: Vurolenatide (DB18440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vurolenatide - 50 mg biweekly SC administration, PBO alternate weeks
Study: NCT04988997
Drug: Vurolenatide 100mg/PBO
DrugBank: Vurolenatide (DB18440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vurolenatide - 100 mg biweekly SC administration, PBO alternate weeks
Study: NCT04988997
Drug: Vurolenatide 50/50 mg
DrugBank: Vurolenatide (DB18440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vurolenatide - 50 mg weekly SC administration
Study: NCT04990752
Drug: ulinastatin
Normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the ulinastatin group, early application of ulinastatin was performed for inflammation management and organ protection before ECMO initiation.The recommended clinical routine dosage of ulinastatin is 300,000 IU, q8h (continuous administration for more than 5 days).
Study: NCT04216927
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxygen alone will be entrained for placebo arm
Study: NCT05381506
Drug: Orelabrutinib and Gemox
Normalized name: Orelabrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Orelabrutinib Orelabrutinib 200mg, po, qd~Drug: Gemox14 Gemcitabine, Oxaliplatin
Study: NCT06506994
Drug: HRS-9057
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-9057 injection dose 1
Study: NCT06506994
Drug: HRS-9057
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-9057 injection dose 2
Study: NCT06506994
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan tablets
Study: NCT05361642
Drug: Bupivacaine HCl 0.5% Injectable Solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: using nasal block including sphenopalatine ganglion block with general anesthesia to optimize surgical field
Study: NCT05361642
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: using dexmedetomidine with induction of general anesthesia to optimize surgical field
Study: NCT04825990
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg pembrolizumab every 3 weeks plus 300 mg olaparib twice a day (BID) every day starting from Day 1 of Cycle 1.
Study: NCT00636259
Drug: Bicalutamide (Casodex)
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg
Study: NCT00980304
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05262686
Drug: Belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab was intravenously administrated at a dose of 10mg/kg once a month for at least 24 weeks.
Study: NCT05262686
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
Study: NCT04973462
Drug: standard treatment COVID-19 + Triazavirin
Normalized name: covid-19, protein subunit
DrugBank: Triazavirin (DB15622)
Approvals — FDA: no, EMA: no, PMDA: no
Description: to evaluate the efficacy and safety (side effects and / or adverse effects) of Triazavirin and Oseltamivir as treatment of Coronavirus Disease 2019
Study: NCT03859921
Drug: Dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progesterone
Study: NCT04397458
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9% saline on each side
Study: NCT04397458
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine (50mg) on each side
Study: NCT04397458
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3mg preservative-free dexamethasone on each side
Study: NCT05932264
Drug: Apatinib + Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: Apatinib 375 mg po qd; Fluzoparib 100mg po bid
Study: NCT05932264
Drug: Apatinib + Fluzoparib + Adebrelimab
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2: Apatinib 375 mg po qd; Fluzoparib 100mg po bid; Adebrelimab 1200mg, iv, d1, q3w\]
Study: NCT04610736
Drug: Temozolomide Oral Suspension
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One prescribed oral dose (range 75 to 200 mg/m2) once daily for 5 days
Study: NCT05294458
Drug: cotadutide solution for injection
Normalized name: Cotadutide
DrugBank: Cotadutide (DB15194)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cotadutide solution for injection
Study: NCT05216055
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal bupivacaine, 20 mL (13.3 mg/ml) (266 mg) Normal saline 0.9%, 40mL
Study: NCT05331911
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: total intravenous anesthesia with propofol for the partial hepatectomy of hepatocellular carcinoma.
Study: NCT05331911
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC).
Study: NCT00002254
Drug: Alovudine
Normalized name: Alovudine
DrugBank: Alovudine (DB06198)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05117021
Drug: Caudal Epidural Block using 0.25% plain bupivacaine dose 1 ml / kg and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine dose 0.5 ml / kg
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caudal Epidural Block and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine
Study: NCT05768243
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hyaluronic acid is used as an adjunctive treatment to scaling and root planing
Study: NCT04460586
Drug: Omadacycline Injection [Nuzyra]
Normalized name: omadacycline Injection [Nuzyra]
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
Study: NCT04460586
Drug: Omadacycline Oral Tablet [Nuzyra]
Normalized name: omadacycline Oral Tablet [Nuzyra]
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
Study: NCT05229796
Drug: Empagliflozin 10 mg Tab
Normalized name: empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The Empagliflozin 10 mg Tab were administered orally. The plasma concentrations of empagliflozin were determined using an HPLC-MS/MS method. Tolerability and safety were assessed throughout the study. This study included 26 subjects, 26 in each fasting and fed group.
Study: NCT05065567
Drug: Droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 2.5mg droperidol IV